Our history



OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. Its lead product the Urodiag® (CE-IVD) is a urine-based lab test for the surveillance of bladder cancer. The company's pipeline also includes the Prostadiag® test to predict non-evolutive localized prostate cancer and the Colodiag® test for the screening of colorectal cancer.

The management is assumed by a highly qualified team, with complementary expertise and supported by a scientific advisory board representative of the health sector.

 





	
Executive management




	




		



	
		

			
				

					
Claude Hennion, PhD

					

						
President and CEO

					
Dr. Claude Hennion is co-founder of OncoDiag and has more than 30 years
of experience in the management of start-up and valorisation of innovation. Claude has a Ph.D. in Physics from Paris VI University.


					

			
				

					

					

					
Jean-Pierre Roperch, PhD

					

						
Director of Research & Development

					
Dr. Jean-Pierre Roperch is co-founder of OncoDiag and has more than 20 years of experience developing  "In Vitro" Diagnostic in oncology. Jean-Pierre has a Ph.D. in Cellular and Molecular Biology from Paris VI University.

		

	



 




	


 Scientific advisory board




	



	

		
			

				
					

					

						
Pr. Olivier Cussenot, MD, PhDHead of the Department of Urology, Tenon hospital, Sorbonne University, Paris (France)

						


								

						
Pr. Morgan Rouprêt, MDProfessor in the Urology Department of the Pitié-Salpétrière hospital, Sorbonne University, Paris (France)

							

						


								

						
Pr. Eva Compérat, MDHead of pathological anatomy and cytology at Tenon Hospital, Paris (France)

						


								

						
Pr. Maurizio Brausi, MDChairman of the Department of Urology at the AUSL, Modena (Italy).

						


								

						
Pr. Maximilian Burger, MDProfessor of Urology and Chairman of the Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg (Germany).

						


								

						
Pr. Paolo Gontero, MDChairman of the Department of Urology, Molinette Hospital, University of Torino (Italy).

						


								

						
Mr. Hugh Mostafid, MScConsultant Urological Surgeon and honorary senior lecturer at the University of surrey (United Kingdom). Member of the European Association of Urology guidelines panel on non-muscle-invasive bladder cancer.

						


								

						
Pr. Joan Palou, MDProfessor of Urology at the Universita Autonoma and Chief of the Urological Oncology Department at the Fundacio Puigvert in Barcelona (Spain).

						


								

						
Pr. Fred Witjes, MD, PhDProfessor at the Radboud Institute for Molecular Life Sciences (Nijmegen, Netherland). He is specialized in oncological urology, with emphasis on bladder cancer, testicular cancer and prostate cancer.